Have You or Someone You Know Been Diagnosed with Alzheimer’s Disease?
Consider Participating in Athira’s Clinical Trials
The clinical trials of fosgonimeton (ATH-1017) are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease.
Fosgonimeton is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function.
Criteria:You or someone you know may be eligible if you:
♦ Are between 55 and 85 years of age
♦ Have been diagnosed with Alzheimer’s disease
♦ Have a reliable support person or caregiver who is willing to participate in study visits, report on daily activities and oversee or help you with taking fosgonimeton
♦ Are not taking acetylcholinesterase inhibitors (cholinergics) or have not taken within the last 4 weeks prior to screening